Drug intelligence / Profile preview

oleylethanolamide

Development stage
Unknown
Lead developer
Allastir
Modality
Small Molecules
Administration
Oral
01

Overview

Oleylethanolamide (OEA) is a naturally occurring lipid and an endogenous agonist of the peroxisome proliferator-activated receptor-alpha (PPAR-α). It is a fatty acid ethanolamide (FAE) derived from oleic acid that plays a significant role in regulating energy homeostasis and lipid metabolism. OEA is primarily known for its ability to induce satiety and reduce food intake by activating PPAR-α in the proximal small intestine, which subsequently transmits signals to the brain via the vagus nerve. Beyond its effects on appetite and body weight, OEA has been investigated for its potential anti-inflammatory, anti-atherosclerotic, and neuroprotective properties. While it is manufactured as an active pharmaceutical ingredient (API) by companies like Allastir, it is also widely available as a dietary supplement and nutraceutical.

Other names
OEAN-oleoylethanolamineN-oleoylethanolamideoleoylethanolamide
02

Targets

GPR119 (Glucose-dependent insulinotropic receptor)TRPV1 (Transient receptor potential cation channel subfamily V member 1)PPARD (Peroxisome proliferator–activated receptor delta)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on oleylethanolamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on oleylethanolamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call